You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Atherosclerotic Cardiovascular Disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic

Recruiting
  • Atherosclerosis
  • Aortic Valve Disease
  • Thrombotic assessment
  • Measurement of Lp(a)
  • Stevenage, United Kingdom
    East and North Herts NHS Trust
Nov 6, 2023

ASCVD, Coronary Artery Calcification Trial (Notification of patients and clinicians)

Not yet recruiting
  • ASCVD
  • Coronary Artery Calcification
  • Notification of patients and clinicians
  • (no location specified)
May 5, 2023

sessmenT and treAtment In AustraliaN Primary Care

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • +3 more
  • Inclisiran Prefilled Syringe
  • Clayton, Victoria, Australia
    Monash Health
Apr 17, 2023

Qualitative Features of Atherosclerotic Plaques

Active, not recruiting
  • Atherosclerotic Cardiovascular Disease
  • Riga, Latvia
    Pauls Stradins Clinical University Hospital
Dec 5, 2022

Dyslipidemias, Atherosclerotic Cardiovascular Disease Trial in Seoul (Pitavastatin, Pitavastatin plus Ezetemibe, Atorvastatin)

Not yet recruiting
  • Dyslipidemias
  • Atherosclerotic Cardiovascular Disease
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Jan 29, 2023

Apical Periodontitis and Atherosclerotic Cardiovascular Diseases

Recruiting
  • Apical Periodontitis
  • Atherosclerotic Cardiovascular Disease
  • Echo-color-doppler
  • Siena, Italy
    Azienda Ospedaliera Universitaria Senese
Mar 19, 2023

Understand Real-world Awareness and Perceptions for Systemic

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Chronic Kidney Disease (CKD)
  • No treatment given
  • Bangalore, India
    Novo Nordisk Investigational Site
Feb 23, 2023

Inclisiran on Major Adverse Cardiovascular Events in French

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • Inclisiran sodium
  • +3 more
  • (no location specified)
Jul 26, 2023

Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol Trial (Achieving a Target LDL-C level of 25mg/dL=

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • +2 more
  • Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL
  • Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
  • (no location specified)
Mar 14, 2023

The Belgian REAL (BE.REAL) Registry

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • Inclisiran
  • (no location specified)
Feb 3, 2023

Inflammation in People With Cardiovascular Disease (POSEIDON)

Not yet recruiting
  • Cardiovascular Risk
  • +2 more
  • No treatment given
  • (no location specified)
Nov 3, 2023

Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a) Trial (SLN360, Placebo)

Not yet recruiting
  • Cardiovascular Diseases
  • +2 more
  • (no location specified)
Sep 12, 2022

Atherosclerotic Cardiovascular Disease Trial (Notification of CAC, Usual Care)

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • Notification of CAC
  • Usual Care
  • (no location specified)
Jul 28, 2023

Childhood and Teen-age Onset Diabetes

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • +2 more
    • Shanghai, China
      Department of Endocrinology and Metabolic Diseases, Ruijin Hospi
    May 20, 2022

    Hypertension, Hyperlipidemias Trial (Penn Med Healthy Heart Program)

    Not yet recruiting
    • Hypertension
    • Hyperlipidemias
    • Penn Med Healthy Heart Program
    • (no location specified)
    Oct 2, 2023

    Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia Trial in Auckland,

    Recruiting
    • Heterozygous Familial Hypercholesterolemia
    • +2 more
    • Auckland, New Zealand
    • +1 more
    Aug 4, 2022

    Atheroscleroses, Coronary Trial in Seoul (Rosuvastatin and Ezetimibe, Rosuvastatin)

    Active, not recruiting
    • Atheroscleroses, Coronary
    • Seoul, Korea, Republic of
    • +1 more
    Oct 1, 2022

    l Gene Editing Therapy for Cardiovascular Disease

    Not yet recruiting
    • Atherosclerotic Cardiovascular Disease
    • +2 more
      • Auckland, New Zealand
      • +2 more
      Oct 31, 2023

      Immunomodulatory Effects of PCSK9 Inhibition

      Not yet recruiting
      • Atherosclerotic Cardiovascular Disease
      • +3 more
      • Contrast-enhanced CCTA
      • 99mTc-tilmanocept SPECT/CT scanning
      • Boston, Massachusetts
        Massachusetts General Hospital
      Jan 30, 2023

      Dyslipidemia in Patients at High Risk and Very High Risk of

      Recruiting
      • Secondary Prevention
      • +2 more
      • application
      • Leon, Guanajuato, Mexico
        Umae Cmn T1
      Sep 13, 2022

      Atherosclerotic Cardiovascular Disease Trial in Grenoble (Evolocumab 140 MG/ML [Repatha])

      Recruiting
      • Atherosclerotic Cardiovascular Disease
      • Evolocumab 140 MG/ML [Repatha]
      • Grenoble, France
        Grenoble University Hospital
      May 18, 2022

      Atherosclerotic Cardiovascular Disease, Coronary Artery Disease Trial in Stanford (Notification)

      Active, not recruiting
      • Atherosclerotic Cardiovascular Disease
      • Coronary Artery Disease
      • Notification
      • Stanford, California
        Stanford Hospital & Clinics
      Jul 26, 2022

      Dyslipidemias, Atherosclerotic Cardiovascular Disease Trial in Amman

      Not yet recruiting
      • Dyslipidemias
      • Atherosclerotic Cardiovascular Disease
        • Amman, Jordan
        • +1 more
        Nov 23, 2022

        Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)

        Not yet recruiting
        • Primary Prevention of Atherosclerotic Cardiovascular Disease
        • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
        • Placebo in 1.5ml
        • (no location specified)
        Feb 13, 2023

        ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Trial (Evolocumab,

        Not yet recruiting
        • ASCVD
        • +3 more
        • (no location specified)
        Aug 3, 2023